ALIGNMENT HEALTHCARE, INC. (ALHC) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 1.34%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 1.34% | Share-based compensation / revenue. Period ending 2026-06-30. $61.53M ÷ $4.58B × 100 ≈ 1.34% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | 4.58B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 61.53M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 55.00M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $4.58B | $61.53M | $55.00M | (m) | (m) | 1.34% | (m) | (m) |
| 2026-03-31 | (m) | $4.26B | $58.91M | $35.65M | (m) | (m) | 1.38% | (m) | (m) |
| 2025-12-31 | (m) | $3.95B | $62.08M | $14.75M | (m) | (m) | 1.57% | (m) | (m) |
| 2025-09-30 | (m) | $3.64B | $65.20M | $2.49M | (m) | (m) | 1.79% | (m) | (m) |
| 2025-06-30 | (m) | $3.34B | $66.23M | $-24.71M | (m) | (m) | 1.99% | (m) | (m) |
| 2025-03-31 | (m) | $3.00B | $67.47M | $-65.84M | (m) | (m) | 2.25% | (m) | (m) |
| 2024-12-31 | (m) | $2.70B | $71.13M | $-101.56M | (m) | (m) | 2.63% | (m) | (m) |
| 2024-09-30 | (m) | $2.46B | $3.71M | $-120.92M | (m) | (m) | 0.15% | (m) | (m) |
| 2024-06-30 | (m) | $2.22B | $24.00K | $-131.16M | (m) | (m) | 0.00% | (m) | (m) |
| 2024-03-31 | (m) | $1.99B | $-1.12M | $-136.43M | $21.64M | (m) | -0.06% | -6.31× | Reported |
| 2023-12-31 | (m) | $1.80B | $0.00 | $-127.82M | $21.23M | (m) | 0.00% | -6.02× | Reported |
| 2023-09-30 | (m) | $1.70B | $-7.65M | $-138.01M | $20.54M | (m) | -0.45% | -6.72× | Reported |
| 2023-06-30 | (m) | $1.61B | $-2.53M | $-141.66M | $19.68M | (m) | -0.16% | -7.20× | Reported |
| 2023-03-31 | (m) | $1.52B | $-6.07M | $-124.65M | $18.91M | (m) | -0.40% | -6.59× | Reported |
| 2022-12-31 | (m) | $1.43B | $0.00 | $-128.64M | $18.29M | (m) | 0.00% | -7.03× | Reported |
| 2022-09-30 | (m) | $1.37B | (m) | $-120.00M | $17.95M | (m) | (m) | -6.69× | Reported |
| 2022-06-30 | (m) | $1.30B | (m) | $-128.04M | $17.76M | (m) | (m) | -7.21× | Reported |
| 2022-03-31 | (m) | $1.25B | (m) | $-161.88M | $17.60M | (m) | (m) | -9.20× | Reported |
| 2021-12-31 | (m) | $1.17B | $621.00K | $-178.07M | $17.44M | (m) | 0.05% | -10.21× | Reported |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $955.39M | $446.00K | $-5.26M | $16.93M | (m) | 0.05% | -0.31× | Reported |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $753.97M | $0.00 | $-29.48M | $14.90M | (m) | 0.00% | -1.98× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TRUPANION, INC. (TRUP) | United States | $0.984B | |
| MOLINA HEALTHCARE, INC. (MOH) | United States | $10.091B | -1,697.50 |
| CENTENE CORP (CNC) | United States | $30.588B | -6.22 |
| HUMANA INC (HUM) | United States | $45.651B | 18.44 |
| Cigna Group (CI) | United States | $70.160B | 10.44 |
| Elevance Health, Inc. (ELV) | United States | $86.364B | 16.90 |
| UNITEDHEALTH GROUP INC (UNH) | United States | $336.652B | 26.62 |